- Home
- KOD vs BANR Comparison
KOD vs BANR Comparison
Compare KOD & BANR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KOD | BANR |
|---|---|---|
| Founded | 2009 | 1890 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.2B |
| IPO Year | 2018 | 2015 |
Fundamental Metrics
Financial Performance| Metric | KOD | BANR |
|---|---|---|
| Price | $36.16 | $62.88 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 7 | 4 |
| Target Price | $35.43 | ★ $70.00 |
| AVG Volume (30 Days) | ★ 548.2K | 227.3K |
| Earning Date | 05-14-2026 | 04-22-2026 |
| Dividend Yield | N/A | ★ 3.14% |
| EPS Growth | N/A | ★ 15.57 |
| EPS | N/A | ★ 1.60 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $0.73 |
| Revenue Next Year | N/A | $5.69 |
| P/E Ratio | ★ N/A | $39.73 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.33 | $57.05 |
| 52 Week High | $47.84 | $69.83 |
Technical Indicators
Market Signals| Indicator | KOD | BANR |
|---|---|---|
| Relative Strength Index (RSI) | 38.60 | 41.31 |
| Support Level | $21.82 | $61.24 |
| Resistance Level | $46.72 | $65.21 |
| Average True Range (ATR) | 3.01 | 1.41 |
| MACD | -1.28 | -0.52 |
| Stochastic Oscillator | 0.19 | 0.00 |
Price Performance
Historical ComparisonAbout KOD Kodiak Sciences Inc
Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.
About BANR Banner Corporation
Banner Corp is a bank holding company. It wholly owns one subsidiary bank, Banner Bank. The Bank's primary business is that of traditional banking institutions, accepting deposits and originating loans in locations surrounding its offices in Washington, Oregon, California, Idaho, and Utah. Banner Bank also actively participates in the secondary loan markets, engaging in mortgage banking operations largely through the origination and sale of one to four family residential loans.